Condition: Pancreatic Neoplasms
Intervention: Procedure: EUS FNA
Sponsor: Carol Davila University of Medicine and Pharmacy
Recruiting
Feeds
4252 items (4252 unread) in 74 feeds
Acinar Cell Carcinoma
(30 unread)
Acinic Cell Carcinoma
(31 unread)
Adenoid Cystic Carcinoma
(64 unread)
Adrenal Gland Cancer
(328 unread)
Ampulla Of Vater
(31 unread)
Anal Cancer
(336 unread)
Angiosarcoma
(77 unread)
Appendix Cancer
(78 unread)
Bile Duct Cancer
(550 unread)
Brain and CNS
(748 unread)
Carcinoid
(116 unread)
Endocrine/Neuroendocrine
(385 unread)
Gall Bladder Cancer
(131 unread)
Hemangioendothelioma
(30 unread)
Hepatoblastoma
(33 unread)
Pancreas
(55 unread)
Phyllodes
(18 unread)
PMP and Mucinous Tumors
(15 unread)
Rhabdomyosarcoma
(89 unread)
Sarcoma
(1107 unread)
Trial - Adrenal Cancer (15 unread)
-
Connect Your Needle to Your Phone to Increase EUS FNA Diagnostic Yield?
Posted: October 6th, 2017, 2:00pm GMT
-
Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients
Posted: March 14th, 2017, 2:00pm GMT
Conditions: Adrenal Insufficiency; Adrenal Cancer
Intervention: Diagnostic Test: Cosyntropin stimulation test
Sponsor: Bnai Zion Medical Center
Recruiting - verified August 2017 -
Familial Investigations of Childhood Cancer Predisposition
Posted: February 8th, 2017, 3:00pm GMT
Conditions: Acute Leukemia; Adenomatous Polyposis; Adrenocortical Carcinoma; AML; BAP1 Tumor Predisposition Syndrome; Carney Complex; Choroid Plexus Carcinoma; Constitutional Mismatch Repair Deficiency Syndrome; Diamond-Blackfan Anemia; DICER1 Syndrome; Dyskeratosis Congenita; Emberger Syndrome; Familial Acute Myeloid Leukaemia; Familial Adenomatous Polyposis; Fanconi Anemia; Familial Cancer; Familial Wilms Tumor; Familial Neuroblastoma; GIST; Hereditary Breast and Ovarian Cancer; Hereditary Paraganglioma-Pheochromocytoma Syndrome; Hodgkin Lymphoma; Juvenile Polyposis; Li-Fraumeni Syndrome; Lynch Syndrome; MDS; Melanoma Syndrome; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2; Neuroblastoma; Neurofibromatosis Type 1; Neurofibromatosis Type II; Nevoid Basal Cell Carcinoma Syndrome; Non Hodgkin Lymphoma; Noonan Syndrome and Other Rasopathy; Overgrowth Syndromes; Pancreatic Cancer; Peutz-Jeghers Syndrome; Pheochromocytoma/Paraganglioma; PTEN Hamartoma Tumor Syndrome; Retinoblastoma; Rhabdoid Tumor Predisposition Syndrome; Rhabdomyosarcoma; Rothmund-Thomson Syndrome; Tuberous Sclerosis; Von Hippel-Lindau Disease
Intervention:
Sponsor: St. Jude Children's Research Hospital
Recruiting -
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Posted: December 28th, 2016, 3:00pm GMT
Conditions: Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Lenvatinib; Other: Quality-of-Life Assessment
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting -
Improving Symptom Self-management in Adolescents & Young Adults With Cancer
Posted: November 6th, 2016, 2:00pm GMT
Conditions: Symptom Clusters; Cancer
Intervention: Device: Computer Symptom Capture Tool
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI); St. Baldrick's Foundation
Recruiting -
Type 1 Multiple Endocrine Neoplasia Cohort Study
Posted: August 31st, 2016, 2:00pm GMT
Condition: Type 1-Multiple Endocrine Neoplasia Syndrome
Intervention:
Sponsor: Centre Hospitalier Universitaire Dijon
Recruiting - verified August 2017 -
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Posted: August 9th, 2016, 2:00pm GMT
Condition: Von Hippel-Lindau Syndrome
Interventions: Drug: Ranibizumab; Drug: E10030
Sponsor: National Eye Institute (NEI)
Recruiting -
Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention
Posted: July 29th, 2015, 2:00pm GMT
Condition: Smoking Cessation
Interventions: Behavioral: Group Cognitive Behavioral Therapy; Behavioral: General Health Education; Drug: Transdermal Nicotine Patch
Sponsors: University of Miami; H. Lee Moffitt Cancer Center and Research Institute
Recruiting -
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Posted: June 10th, 2013, 2:00pm GMT
Condition: Medulloblastoma
Interventions: Radiation: Craniospinal Irradiation with boost to the primary tumor site; Drug: Cyclophosphamide; Drug: Cisplatin; Drug: Vincristine; Drug: Vismodegib; Drug: Pemetrexed; Drug: Gemcitabine; Other: Aerobic Training; Other: Neurocognitive Remediation
Sponsors: St. Jude Children's Research Hospital; Genentech, Inc.; National Cancer Institute (NCI)
Recruiting -
An Interactive Preventive Health Record to Increase Colorectal Cancer Screening
Posted: April 23rd, 2013, 2:00pm GMT
Condition: Colorectal Cancer Screening
Interventions: Behavioral: MyCRCS+Prefs; Behavioral: MyCRCS+Prefs+Barriers
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting -
A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Posted: April 12th, 2013, 2:00pm GMT
Condition: Bone Metastasis
Intervention: Device: ExAblate MRgFUS
Sponsor: InSightec
Recruiting -
Natural History Study of Children and Young Adults With Medullary Thyroid Cancer
Posted: August 9th, 2012, 2:00pm GMT
Condition: Medullary Thyroid Carcer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
Study of Adrenal Gland Tumors
Posted: June 28th, 2000, 2:00pm GMT
Condition: Adrenal Gland Neoplasm
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting -
Diagnosis of Pheochromocytoma
Posted: March 2nd, 2000, 3:00pm GMT
Condition: Pheochromocytoma
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting -
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Posted: November 3rd, 1999, 3:00pm GMT
Condition: Cushing Syndrome
Interventions: Drug: Pentetreotide; Drug: 18-F-fluorodeoxyglucose; Drug: (18F)-L-3,4-dihydroxyophenylalanine (18F-DOPA)
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting